留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x

阿德福韦酯和替比夫定对肾功能影响的研究进展

赵康路

downloadPDF
文章导航 > 分子影像学杂志  > 2019 >  42(2): 238-240
赵康路. 阿德福韦酯和替比夫定对肾功能影响的研究进展[J]. 分子影像学杂志, 2019, 42(2): 238-240. doi: 10.12122/j.issn.1674-4500.2019.02.22
引用本文: 赵康路. 阿德福韦酯和替比夫定对肾功能影响的研究进展[J]. 分子影像学杂志, 2019, 42(2): 238-240. doi: 10.12122/j.issn.1674-4500.2019.02.22
shu
KangLu ZHAO. Advances in the effects of adefovir and telbivudine on renal function[J]. Journal of Molecular Imaging, 2019, 42(2): 238-240. doi: 10.12122/j.issn.1674-4500.2019.02.22
Citation: KangLu ZHAO. Advances in the effects of adefovir and telbivudine on renal function[J]. Journal of Molecular Imaging, 2019, 42(2): 238-240. doi: 10.12122/j.issn.1674-4500.2019.02.22
shu

阿德福韦酯和替比夫定对肾功能影响的研究进展

doi: 10.12122/j.issn.1674-4500.2019.02.22

  • 浙江大学医学院附属第四医院，浙江 义乌 322000

详细信息
    作者简介:

    赵康路，硕士，医师，E-mail：8016019@zju.edu.cn

Advances in the effects of adefovir and telbivudine on renal function

  • The Fourth Affiliated Hospital, Medical School of Zhejiang University, Yiwu 322000, China

    摘要
  • 摘要: 阿德福韦酯和替比夫定均是抗病毒药物，临床上常用于抗乙肝病毒治疗。在慢性乙型肝炎的治疗过程中，阿德福韦酯主要用于对拉米夫定、替比夫定或恩替卡韦耐药的联合治疗中，而替比夫定作为妊娠B级药物，在慢性乙型肝炎的妊娠女性患者治疗中发挥更好的优势。临床研究显示阿德福韦酯容易引起肾功能损伤，而替比夫定可以发挥改善肾功能的作用，且与阿德福韦酯联合使用可以减少阿德福韦酯引起的肾功能受损。本文将两种药物对肾功能的影响进行综述。

     

    Abstract: Adefovir dipivoxil and telbivudine are antiviral drugs commonly used in the treatment of hepatitis B virus. In the treatment of chronic hepatitis B, Adefovir dipivoxil is mainly used in combination therapy for patients who are resistant to Lamivudine, Telbivudine or Entecavir. Telbivudine, as a grade B drug for pregnancy, plays a better role in the treatment of pregnant women with chronic hepatitis B. Clinical studies have shown that Adefovir Dipivoxil is prone to cause renal impairment, and Telbivudine can improve renal function. Combined with Adefovir Dipivoxil, it can reduce impaired renal function caused by Adefovir Dipivoxil . This article reviews the effects of two drugs on renal function.

     

    • HTML全文
    • 参考文献(30)
  • [1] Unwin RJ. Back to the future: renal tubular acidosis then and now[J]. QJM, 2012, 105(9): 915-6. doi: 10.1093/qjmed/hcs134
    [2] Argyropoulos CP, Chen SS, Ng YH, et al. Rediscovering beta-2 microglobulin as a biomarker across the spectrum of kidney diseases[J]. Front Med(Lausanne), 2017, 53(10): 73-85.
    [3] Selamet U, Tighiouart H, Sarnak MJ, et al. Relationship of dietary phosphate intake with risk of end-stage renal disease andmortality in chronic kidney disease stages 3-5:the modification of diet in renal disease study[J]. Kidney Int, 2016, 89(1): 176-84. doi: 10.1038/ki.2015.284
    [4] Javaid A, Jaffri SA, Munir I, et al. Comparison of measured glomerular filtration rates with isotope infusion and with the modification of diet in renal disease equation in cancer patients with raised serum creatinine[J]. Saudi J Kidney Dis Transpl, 2015, 26(2): 293-6. doi: 10.4103/1319-2442.152422
    [5] Czajka A, A n. Hyperglycemia induced damage to mitochondrial respiration in renal mesangial and tubular cells:implications for diabetic nephropathy[J]. Redox Biol, 2016, 38(10): 100-7.
    [6] Jia HY, Ding F, Chen JY, et al. Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B[J]. World J Gastroenterol, 2015, 21(12): 3657-62. doi: 10.3748/wjg.v21.i12.3657
    [7] Shimizu M, Furusyo N, Ikezaki H, et al. Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B[J]. World J Gastroenterol, 2015, 21(7): 2116-23. doi: 10.3748/wjg.v21.i7.2116
    [8] Zhang Y, Li J, Li FH, et al. Neutrophil gelatinase-associated lipocalin accurately predicts renal tubular injury in patients with chronic hepatitis B treated with nucleos(t)ide analogs[J]. Hepatol Res, 2018, 48(2): 144-52. doi: 10.1111/hepr.v48.2
    [9] Koda R, Tsuchida M, Iino N, et al. A case of hypophosphatemic osteomalacia associated with adefovir-induced fanconi syndrome initially diagnosed as diabetic kidney disease and vitamin D deficiency[J]. Intern Med, 2018, 217(10): 1206-15.
    [10] Lin Y, Pan F, Wang Y, et al. Adefovir dipivoxil-induced Fanconi syndrome and its predictive factors: a study of 28 cases[J]. Oncol Lett, 2017, 13(1): 307-14. doi: 10.3892/ol.2016.5393
    [11] Li X, Shen M, Sun WJ, et al. Misdiagnosis of bone metastasis cancer after using adefovir dipivoxi in a hepatitis B patient with fanconi syndrome[J]. Indian J Hematol Blood Transfus, 2016, 32(Suppl 1): 329-31.
    [12] Lee YS, Kim BK, Lee HJ, et al. Pathologic femoral neck fracture due to fanconi syndrome induced by adefovir dipivoxil therapy for hepatitis B[J]. Clin Orthop Surg, 2016, 8(2): 232-6. doi: 10.4055/cios.2016.8.2.232
    [13] Xu LJ, Jiang Y, Liao RX, et al. Low-dose adefovir dipivoxil May induce Fanconi syndrome:clinical characteristics and long-term follow-up for Chinese patients[J]. Antivir Ther, 2015, 20(6): 603-11. doi: 10.3851/IMP2954
    [14] Wang BF, Wang Y, Wang BY, et al. Osteomalacia and fanconi's syndrome caused by long-term low-dose adefovir dipivoxil[J]. J Clin Pharm Ther, 2015, 40(3): 345-8. doi: 10.1111/jcpt.2015.40.issue-3
    [15] Zhu LN, Mou LJ, Hu Y, et al. Fanconi syndrome caused by low-dose adefovir dipivoxil[J]. Saudi Med J, 2014, 35(3): 309-13.
    [16] Zhu S, Yang YH, Gao RW, et al. Clinical features of hypophosphatemic osteomalacia induced by long-term low-dose adefovir dipivoxil[J]. Drug Des Devel Ther, 2018, 12(12): 41-5.
    [17] Tanaka M, Suzuki F, Seko Y, et al. Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B[J]. J Gastroenterol, 2014, 49(3): 470-80. doi: 10.1007/s00535-013-0779-0
    [18] Luo Q, Deng Y, Cheng F, et al. Relationship between nephrotoxicity and long-term adefovir dipivoxil therapy for chronic hepatitis B: a meta-analysis[J]. Medicine (Baltimore), 2016, 95(50): e5578-86. doi: 10.1097/MD.0000000000005578
    [19] Su Q, Liu Y, Li J. Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B[J]. Medicine (Baltimore), 2018, 97(34): e12089-97. doi: 10.1097/MD.0000000000012089
    [20] Kader C, Sunbul M, Das YK, et al. Telbivudine attenuates gentamicin-induced kidney injury in rats[J]. Int J Antimicrob Agents, 2017, 49(5): 595-602. doi: 10.1016/j.ijantimicag.2017.01.015
    [21] Lin YS, Shih SC, Wang HY, et al. Comparison of telbivudineand entecavir on the change of off-treatment eGFR after 3 years of treatment in non-cirrhotic chronic hepatitis B patients[J]. BMC Gastroenterol, 2017, 17(1): 22-35. doi: 10.1186/s12876-017-0582-0
    [22] Lin KH, Chen YL, Lin PY, et al. A Follow-Up studyon the renal protective efficacy of telbivudine for hepatitis B Virus-InfectedTaiwanese patients after living donor liver transplant[J]. Exp Clin Transplant, 2017, 15(1): 65-8.
    [23] Lin MT, Yen YH, Tsai MC, et al. Comparison of theEfficacies and safety of combined therapy between telbivudine plus adefovir andLamivudine plus adefovir in patients with hepatitis B virus infection inReal-World practice[J]. PLoS One, 2016, 11(11): e0165416-25. doi: 10.1371/journal.pone.0165416
    [24] Chen J, Li D. Telbivudine attenuates UUO-induced renal fibrosis via TGF-β/Smad and NF-κB signaling[J]. Int Immunopharmacol, 2018, 55(10): 1-8.
    [25] Xu Y, Nie ZW. Telbivudine and adefovir dipivoxil combination therapy improves renal function in patients with chronic hepatitis B: a strobe-compliant article[J]. Medicine (Baltimore), 2018, 97(48): e13430. doi: 10.1097/MD.0000000000013430
    [26] Li W, Zhang D. Influence of monotherapy with telbivudine or entecavir on renal function in patients with chronic hepatitis B[J]. Chin J Hepatol, 2015, 23(6): 407-11.
    [27] Hsu CW, Chen YC, Chang ML, et al. Durability of Telbivudine-associated improvement of renal function following withdrawal or switching of antivirals in chronic hepatitis B patients[J]. Open Forum Infect Dis, 2018, 5(1): 271-82.
    [28] Cholongitas E, Vasiliadis T, Goulis I, et al. Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease[J]. J Viral Hepat, 2015, 22(7): 574-80. doi: 10.1111/jvh.2015.22.issue-7
    [29] Lee WC, Wu TH, Wang YC, et al. Renal function improvement by telbivudine in liver transplant recipients with chronic kidney disease[J]. Biomed Res Int, 2017, 93(24): 310-26.
    [30] Liu J, Yao N, Zhao Y. Improvement of telbivudine on renal function and massive proteinuria: A case report[J]. J Viral Hepat, 2017, 24(1, SI): 75-7. doi: 10.1111/jvh.12621
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  1440
  • HTML全文浏览量:  619
  • PDF下载量:  5
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-02-05
  • 刊出日期:  2019-04-01

目录

    /

    返回文章
    返回
    • 版权所有© 2013《分子影像学杂志》编辑部 ICP备00000000号
    • 重点提示: Adobe Reader6可能造成全文显示不正常，请升级为Adobe Reader7或更高。
    • 地址: 广东省广州市广州大道北1838号 Tel: 020-61648176 E-mail: 

    本系统由 北京仁和汇智信息技术有限公司 开发  技术支持：info@rhhz.net

    x 关闭 永久关闭

    关于《分子影像学杂志》变更刊期通知

    各位专家、作者、读者：

    为了缩短出版时滞，促进科研成果的快速传播，我刊自2024年1月起，刊期由双月刊变更为月刊。本刊主要栏目有：基础研究、临床研究、技术方法、综述等。

    感谢各位专家、作者、读者长期以来对我刊的支持与厚爱！

    南方医科大学学报编辑部

    《分子影像学杂志》

    2023年12月27日